Article information
Abstract
The introduction of highly active antiretroviral treatment (HAART) in 1996 radically changed the clinical course of human immunodeficiency virus (HIV) infection as it led to a dramatic reduction in mortality in these patients. However, these treatments have their limitations, including adverse effects, therapeutic failure, pharmacokinetic interactions, the development of resistance, and abnormal immune responses. In this article we review the current situation of cutaneous drug reactions in HIV-infected patients.
Key words:
TARGA
VIH
HAART
HIV
cutaneous drug reactions
Resumen
La introducción del tratamiento antirretroviral de gran actividad (TARGA) en 1996 supuso un cambio radical en la historia natural de la infección por el virus de la inmunodeficiencia humana (VIH) al lograr reducir drásticamente la mortalidad en estos pacientes. No obstante, estos tratamientos no están exentos de limitaciones que incluyen efectos adversos, fracaso del tratamiento, interacciones farmacocinéticas, aparición de resistencias y respuestas inmunes anómalas. En este artículo se revisa la situación actual de las reacciones cutáneas adversas a fármacos en los pacientes con infección por el VIH.
Palabras clave:
TARGA
VIH
efectos cutáneos adversos
Full text is only aviable in PDF
References
[1.]
Y. Mouton, S. Alfandari, M. Valette, F. Cartier, P. Dellamonica, G. Humbert, et al.
Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération National des Centres de Lutte contre le SIDA.
AIDS, 11 (1997), pp. 101-105
[2.]
F.J. Palella Jr, K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, G.A. Satten, et al.
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.
N Engl J Med, 338 (1998), pp. 853-860
[3.]
J.E. Kaplan, D. Hanson, M.S. Dworkin, T. Frederick, J. Bertolli, M.L. Lindegren, et al.
Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.
Clin Infect Dis, 30 (2000), pp. S5-S14
[4.]
J.C. Gea-Banacloche, H. Clifford Lane.
Immune reconstitution in HIV infection.
AIDS, 13 (1999), pp. S25-S38
[5.]
N. Jahnke, V. Montessori, R. Hogg, A. Anis, M. O'Shaugnessy, J. Montaner.
Impact of triple drug therapy on morbidity, mortality and cost.
AIDS Rev, 1 (1999), pp. 57-60
[6.]
P. Viciana, P. Miralles-Martin, H. Knobel, J.M. Gatell.
Prevention of opportunistic infections in the protease inhibitor era.
Enferm Infecc Microbiol Clin, 16 (1998), pp. 1-10
[7.]
C. Michelet, C. Arvieux, C. Francois, J.M. Besnier, J.P. Rogez, J.P. Breux, et al.
Opportunistic infections occurring during highly active antiretroviral treatment.
AIDS, 12 (1998), pp. 1815-1822
[8.]
D. Torre, F. Speranza, R. Martegani.
Impact of highly active antiretroviral therapy on organ-specific manifestations of HIV-1 infection.
HIV Med, 6 (2005), pp. 66-78
[9.]
M. Guillaume, P. Pavese, C. Decouchon, J.P. Brion, J.P. Stahl.
Subcutaneous abscesses due to Mycobacterium avium due to a reconstitution syndrome in AIDS patients.
Med Mal Infect, 36 (2006), pp. 429-431
[10.]
A. Bourgarit, G. Carcelain, V. Martinez, C. Lascoux, V. Delcey, B. Gicquel, et al.
Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients.
AIDS, 20 (2006), pp. 1-7
[11.]
N.F. Crum, K.A. Blade.
Cytomegalovirus retinitis after immune reconstitution.
AIDS Read, 15 (2005), pp. 186-188
[12.]
J. Gilquin, J.P. Viard, V. Jubault, C. Sert, M.D. Kazatchkine.
Delayed occurrence of Graves’ disease after immune restoration with HAART. Highly active antiretroviral therapy.
Lancet, 352 (1998), pp. 1907-1908
[13.]
J. Portilla, V. Boix, F. Roman, S. Reus, E. Merino.
Progressive multifocal leukoencephalopathy treated with cidofovir in HIV-infected patients receiving highly active anti-retroviral therapy.
J Infect, 41 (2000), pp. 182-184
[14.]
J. Mayo, J. Collazos, E. Martínez.
Progressive multifocal leukoencephalopathy following initiation of highly active antiretroviral therapy.
AIDS, 12 (1998), pp. 1720-1722
[15.]
J.C. Walsh, C.E. Costello, M.R. Nelson.
Response of HIVassociated thrombocytopenia to triple agent antiretroviral therapy.
AIDS, 11 (1997), pp. 399-400
[16.]
J.J. Monsuez, D. Vittecoq, L. Musset, M. Alemanni, E. Dussaix, B. Autran.
Arthralgias and cryoglobulinemia during protease inhibitor therapy in a patient infected with human immunodeficiency virus and hepatitis C virus.
Arthritis Rheum, 41 (1998), pp. 740-743
[17.]
López-Aldeguer J, Pulido F, Polo R y panel de expertos de GESIDA y Plan Nacional sobre el Sida. Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2007). Enferm Infecc Microbiol Clin. 2007;25:32-53.
[18.]
D.A. Cooper, J.M. Lange.
Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.
Lancet Infect Dis, 4 (2004), pp. 426-436
[19.]
A. Rotunda, R.J. Hirsch, N. Scheinfeld, J.M. Weinberg.
Severe cutaneous reactions associated with the use of human immunodeficiency virus medications.
Acta Derm Venereol, 83 (2003), pp. 1-9
[20.]
M. Eliaszewicz, A. Flahault, J.C. Roujeau, A.M. Fillet, D. Challine, S. Mansouri, et al.
Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS.
J Am Acad Dermatol, 47 (2002), pp. 40-46
[21.]
K.J. Smith, H.G. Skelton, J. Yeager, R. Ledsky, T.H. Ng, K.F. Wagner.
Increased drug reactions in HIV-1-positive patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. The Military Medical Consortium for the Advancement of Retroviral Research (MMCARR).
Clin Exp Dermatol, 22 (1997), pp. 118-123
[22.]
C. Roudier, E. Caumes, O. Rogeaux, F. Bricaire, M. Gentilini.
Adverse cutaneous reactions to trimethoprimsulfamethoxazole in patients with the acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia.
Arch Dermatol, 130 (1994), pp. 1383-1386
[23.]
H.M. Heller.
Adverse cutaneous drug reactions in patients with human immunodeficiency virus-1 infection.
Clin Dermatol, 18 (2000), pp. 485-489
[24.]
R.L. Hengel, N.B. Watts, J.L. Lennox.
Benign symmetric lipomatosis associated with protease inhibitors.
Lancet, 350 (1997), pp. 1596
[25.]
I. Herry, L. Bernard, P. de Truchis, C. Perronne.
Hypertrophy of the breasts in a patient treated with indinavir.
Clin Infect Dis, 25 (1997), pp. 937-938
[26.]
E. Martínez, J.M. Gatell.
Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome.
Curr Opin Infect Dis, 12 (1999), pp. 13-19
[27.]
A. Shevitz, C.A. Wanke, J. Falutz, D.P. Kotler.
Clinical perspectives on HIV-associated lipodystrophy syndrome: an update.
AIDS, 15 (2001), pp. 1917-1930
[28.]
E. Bernasconi.
Metabolic effects of protease inhibitor therapy.
AIDS Read, 9 (1999), pp. 254-256
[29.]
A. Carr, K. Samaras, D.J. Chisholm, D.A. Cooper.
Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.
Lancet, 351 (1998), pp. 1881-1883
[30.]
S. Madge, S. Kinloch-de-Loes, D. Mercey, M.A. Johnson, I.V. Weller.
Lipodystrophy in patients naive to HIV protease inhibitors.
AIDS, 13 (1999), pp. 735-737
[31.]
R. Polo, J. Verdejo, S. Martínez-Rodríguez, P. Madrigal, M. González-Muñoz.
Lipoatrophy, fat accumulation, and mixed syndrome in protease inhibitor-naive HIV-infected patients.
J Acquir Immune Defic Syndr, 25 (2000), pp. 284-286
[32.]
K.A. Lichtenstein, D.J. Ward, A.C. Moorman, K.M. Delaney, B. Young, F.J. Palella Jr, et al.
Clinical assessment of HIV-associated lipodystrophy in an ambulatory population.
AIDS, 15 (2001), pp. 1389-1398
[33.]
A. Carr, D.A. Cooper.
Adverse effects of antiretroviral therapy.
Lancet, 356 (2000), pp. 1423-1430
[34.]
S. Duran, M. Saves, B. Spire, V. Cailleton, A. Sobel, P. Carrieri, et al.
Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy.
AIDS, 15 (2001), pp. 2441-2444
[35.]
R. Zerboni, A.G. Angius, M. Cusini, G. Tarantini, G. Carminati.
Lamivudine-induced paronychia.
Lancet, 351 (1998), pp. 1256
[36.]
F. Bouscarat, C. Bouchard, D. Bouhour.
Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir.
N Engl J Med, 338 (1998), pp. 1776-1777
[37.]
J. García-Silva, M. Almagro, C. Pena-Penabad, E. Fonseca.
Indinavir-induced retinoid-like effects: Incidence, clinical features and management.
Drug Saf, 25 (2002), pp. 993-1003
[38.]
C.W. James, K.C. McNelis, D.M. Cohen, S. Szabo, A.K. Bincsik.
Recurrent ingrown toenails secondary to indinavir/ritonavir combination therapy.
Ann Pharmacother, 35 (2001), pp. 881-884
[39.]
M. Alam, R.K. Scher.
Indinavir-related recurrent paronychia and ingrown toenails.
Cutis, 64 (1999), pp. 277-278
[40.]
S.L. Kang-Birken, J.G. Prichard.
Paronychia of the great toes associated with protease inhibitors.
Am J Health Syst Pharm, 56 (1999), pp. 1674-1675
[41.]
A. Tosti, B.M. Piraccini, A. D’Antuono, S. Marzaduri, V. Bettoli.
Paronychia associated with antiretroviral therapy.
Br J Dermatol, 140 (1999), pp. 1165-1168
[42.]
C.W. James, K.C. McNelis, D.M. Cohen, S. Szabo, A.K. Bincsik.
Recurrent ingrown toenails secondary to indinavir/ritonavir combination therapy.
Ann Pharmacother, 35 (2001), pp. 881-884
[43.]
E. Martínez, J. Gatell, Y. Morán, E. Aznar, E. Buira, A. Guelar, et al.
High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors.
Clin Infect Dis, 27 (1998), pp. 1510-1513
[44.]
S.A. Shelburne 3rd, R.J. Hamill, M.C. Rodríguez-Barradas, S.B. Greenberg, R.L. Atmar, D.M. Musher, et al.
Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy.
Medicine (Baltimore), 81 (2002), pp. 213-227
[45.]
S.A. Shelburne 3rd, R.J. Hamill.
The immune reconstitution inflammatory syndrome.
AIDS Rev, 5 (2003), pp. 67-79
[46.]
M. Stoll, R.E. Schmidt.
Immune restoration inflammatory syndromes: apparently paradoxical clinical events after the initiation of HAART.
Curr HIV/AIDS Rep, 1 (2004), pp. 122-127
[47.]
P. Mirmirani, T.A. Maurer, B. Herndier, M. McGrath, M.D. Weinstein, T.G. Berger.
Sarcoidosis in a patient with AIDS: a manifestation of immune restoration syndrome.
J Am Acad Dermatol, 41 (1999), pp. 285-286
[48.]
J.C. Pascual, I. Belinchón, J.F. Silvestre, G. Vergara, M. Blanes, J. Banuls, et al.
Sarcoidosis after highly active antiretroviral therapy in a patient with AIDS.
Clin Exp Dermatol, 29 (2004), pp. 156-158
[49.]
A.J. Chamberlain, K. Hollowood, R.J. Turner, I. Byren.
Tumid lupus erythematosus occurring following highly active antiretroviral therapy for HIV infection: a manifestation of immune restoration.
J Am Acad Dermatol, 51 (2004), pp. S161-S165
[50.]
C.A. Fisher, P.R. McPoland.
Azidothymidine-induced nail pigmentation.
Cutis, 43 (1989), pp. 552-554
[51.]
R.G. Greenberg, T.G. Berger.
Nail and mucocutaneous hyperpigmentation with azidothymidine therapy.
J Am Acad Dermatol, 22 (1990), pp. 327-330
[52.]
C. Bendick, H. Rasokat, G.K. Steigleder.
Azidothymidine-induced hyperpigmentation of skin and nails.
Arch Dermatol, 125 (1989), pp. 1285-1286
[53.]
A.P. Panwalker.
Nail pigmentation in the acquired immunodeficiency syndrome (AIDS).
Ann Intern Med, 107 (1987), pp. 943-944
[54.]
A. Azon-Masoliver, J. Mallolas, J. Gatell, T. Castel.
Zidovudine-induced nail pigmentation.
Arch Dermatol, 124 (1988), pp. 1570-1571
[55.]
P.A. Furth, A.M. Kazakis.
Nail pigmentation changes associated with azidothymidine (zidovudine).
Ann Intern Med, 107 (1987), pp. 350
[56.]
G. Vaiopoulos, J. Mangakis, A. Karabinis, A. Kourtis, P. Fourtounis, P. Fessas.
Nail pigmentation and azidothymidine.
Ann Intern Med, 108 (1988), pp. 777
[57.]
M.L. Obuch, G. Baker, R.I. Roth, T.S. Yen, J. Levin, T.G. Berger.
Selective cutaneous hyperpigmentation in mice following zidovudine administration.
Arch Dermatol, 128 (1992), pp. 508-513
[58.]
J. Sahai, B. Conway, D. Cameron, G. Garber.
Zidovudine-associated hypertrichosis and nail pigmentation in an HIV-infected patient.
AIDS, 5 (1991), pp. 1395-1396
[59.]
N.E. Klutman, D.R. Hinthorn.
Excessive growth of eyelashes in a patient with AIDS being treated with zidovudine.
N Engl J Med, 324 (1991), pp. 1896
[60.]
R.A. Torres, R.Y. Lin, M. Lee, M.R. Barr.
Zidovudine-induced leukocytoclastic vasculitis.
Arch Intern Med, 152 (1992), pp. 850-851
[61.]
D.G. Diven, R.C. Newton, K.M. Ramsey.
Heightened cutaneous reactions to mosquito bites in patients with acquired immunodeficiency syndrome receiving zidovudine.
Arch Intern Med, 148 (1988), pp. 2296
[62.]
P. Herranz, M.L. Fernández-Díaz, R. de Lucas, J. González-García, M. Casado.
Cutaneous vasculitis associated with didanosine.
Lancet, 344 (1994), pp. 680
[63.]
A. Parneix-Spake, S. Bastuji-Garin, Y. Levy, M.L. Dubreuil-Lemaire, J.C. Roujeau.
Didanosine as probable cause of Stevens-Johnson syndrome.
Lancet, 340 (1992), pp. 857-858
[64.]
M. Just, J.M. Carrascosa, M. Ribera, I. Bielsa, C. Ferrándiz.
Dideoxyinosine-associated Ofuji papuloerythroderma in an HIV-infected patient.
Dermatology, 195 (1997), pp. 410-411
[65.]
S. Ofuji, F. Furukawa, Y. Miyachi, S. Ohno.
Papuloerythroderma.
Dermatologica, 169 (1984), pp. 125-130
[66.]
G. Boden, H. Degreef, J.J. van den Oord.
Papuloerythroderma: report of a European case.
Dermatology, 186 (1993), pp. 193-196
[67.]
D. Ingrand, J. Weber, C.A. Boucher, C. Loveday, C. Robert, A. Hill, et al.
Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group.
AIDS, 9 (1995), pp. 1323-1329
[68.]
K.J. Smith, R. Buckley, H. Skelton.
Lamivudine (3TC)-induced contact dermatitis.
Cutis, 65 (2000), pp. 227-229
[70.]
R. Zerboni, A.G. Angius, M. Cusini, G. Tarantini, G. Carminati.
Lamivudine-induced paronychia.
Lancet, 351 (1998), pp. 1256
[71.]
M.C. McNeely, R. Yarchoan, S. Broder, T.J. Lawley.
Dermatologic complications associated with administration of 2’,3’-dideoxycytidine in patients with human immunodeficiency virus infection.
J Am Acad Dermatol, 21 (1989), pp. 1213-1217
[72.]
E. Tancrede-Bohin, F. Grange, I. Bournerias, J.C. Roujeau, J.C. Guillaume.
Hypersensitivity syndrome associated with zalcitabine.
Lancet, 347 (1996), pp. 971
[73.]
R. Yarchoan, C.F. Perno, R.V. Thomas, R.W. Klecker, J.P. Allain, R.J. Wills, et al.
Phase I studies of 2’,3’-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).
Lancet, 1 (1988), pp. 76-81
[74.]
M.A. Fischl, K. Stanley, A.C. Collier, J.M. Arduino, D.S. Stein, J.E. Feinberg, et al.
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.
Ann Intern Med, 122 (1995), pp. 24-32
[75.]
D. Abrams, D. Cotton, M. Markowitz, K. Mayer.
AIDS/HIV Treatment Directory, 9 (1997), pp. 24
[76.]
J.C. Adkins, D.H. Peters, D. Faulds.
Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.
Drugs, 53 (1997), pp. 1054-1080
[77.]
P. Keiser, N. Nassar, D. Skiest, C. Andrews, B. Yazdani, A. White, et al.
Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction.
Int J STD AIDS, 14 (2003), pp. 478-481
[78.]
D. King, S. Tomkins, A. Waters, P.J. Easterbrook, L.M. Thurmond, D.E. Thorborn, et al.
Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects.
J Allergy Clin Immunol, 115 (2005), pp. 1081-1087
[79.]
P.S. Hervey, C.M. Perry.
Abacavir: a review of its clinical potential in patients with HIV infection.
Drugs, 60 (2000), pp. 447-479
[80.]
P.G. Clay.
The abacavir hypersensitivity reaction: a review.
Clin Ther, 24 (2002), pp. 1502-1514
[81.]
J. Berenguer, M.J. Pérez-Elías, J.M. Bellón, H. Knobel, P. Rivas-González, J.M. Gatell, Abacavir, Lamivudine, and Zidovudine Cohort Study Group, et al.
Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort.
J Acquir Immune Defic Syndr, 41 (2006), pp. 154-159
[82.]
R.G. Hewitt.
Abacavir hypersensitivity reaction.
Clin Infect Dis, 34 (2002), pp. 1137-1142
[83.]
C. Fontaine, J.B. Guiard-Schmid, L. Slama, A. Essid, T. Lukiana, E. Rondeau, et al.
Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate.
AIDS, 19 (2005), pp. 1927-1928
[84.]
S. Dargere, R. Verdon, K. Bouhier, C. Bazin.
Disseminated intravascular coagulation as a manifestation of abacavir hypersensitivity reaction.
AIDS, 16 (2002), pp. 1696-1697
[85.]
M. Shapiro, K.M. Ward, J.J. Stern.
A near-fatal hypersensitivity reaction to abacavir: case report and literature review.
AIDS Read, 11 (2001), pp. 222-226
[86.]
M. Montero, L. García-Gibert, A.M. Giménez-Arnau, H. Knobel.
Necrólisis epidérmica tóxica asociada a abacavir.
Enferm Infecc Microbiol Clin, 23 (2005), pp. 247
[87.]
J. Krischer, O. Rutschmann, S.V. Roten, M. Harms, J.H. Saurat, M. Pechère.
Neutrophil eccrine hidradenitis in a patient with AIDS.
J Dermatol, 25 (1998), pp. 199-200
[88.]
J. Borrás-Blasco, A. Navarro-Ruiz, C. Borrás, E. Casterá.
Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection.
J Antimicrob Chemother, 62 (2008), pp. 879-888
[89.]
I.J. Woolley, A.J. Veitch, C.S. Harangozo, M. Moyle, T.M. Korman.
Lichenoid drug eruption to tenofovir in an HIV/hepatitis B virus co-infected patient.
AIDS, 18 (2004), pp. 1857-1858
[91.]
P.A. Fox, F.C. Boag, D.A. Hawkins, N. Francis.
Acute porphyria following commencement of indinavir.
AIDS, 13 (1999), pp. 622-623
[92.]
W.J. Rietsema.
Fever, erythroderma, abdominal pain, and renal failure following initiation of indinavir therapy.
Clin Infect Dis, 25 (1997), pp. 1268-1269
[93.]
R. Teira, Z. Zubero, J. Muñoz, J. Baraia-Etxaburu, J.M. Santamaría.
Stevens-Johnson syndrome caused by indinavir.
Scand J Infect Dis, 30 (1998), pp. 634-635
[94.]
H.B. Fung, R.A. Pecini, S.T. Brown, C.A. Gropper.
Indinavir-associated maculopapular eruption.
Pharmacotherapy, 19 (1999), pp. 1328-1330
[95.]
E. Toma, R. Therrien.
Gynecomastia during indinavir antiretroviral therapy in HIV infection.
AIDS, 12 (1998), pp. 681-682
[96.]
I. Herry, L. Bernard, P. de Truchis, C. Perronne.
Hypertrophy of the breasts in a patient treated with indinavir.
Clin Infect Dis, 25 (1997), pp. 937-938
[97.]
F. Bouscarat, M.H. Prevot, S. Matheron.
Alopecia associated with indinavir therapy.
N Engl J Med, 341 (1999), pp. 618
[98.]
A. D’Arminio Monforte, L. Testa, M. Gianotto, A. Gori, F. Franzetti, S. Sollima, et al.
Indinavir-related alopecia.
AIDS, 12 (1998), pp. 328
[99.]
F. Bouscarat, C. Bouchard, D. Bouhour.
Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir.
N Engl J Med, 338 (1998), pp. 1776-1777
[100.]
M. Alam, R.K. Scher.
Indinavir-related recurrent paronychia and ingrown toenails.
Cutis, 64 (1999), pp. 277-278
[101.]
R. Colebunders, M. Vandenbruaene.
The changing spectrum of the cutaneous manifestation of HIV disease.
Arch Dermatol, 135 (1999), pp. 471
[102.]
S.L. Hagerty, D.P. Ascher.
Spontaneous bleeding associated with the use of the protease inhibitor ritonavir in a hemophiliac patient with human immunodeficiency virus infection.
Pediatr Infect Dis J, 17 (1998), pp. 929-930
[103.]
C. Ginsburg, D. Salmon-Ceron, D. Vassilief, C. Rabian, C. Rotschild, M. Fontenay-Roupie, et al.
Unusual occurrence of spontaneous haematomas in three asymptomatic HIV-infected haemophilia patients a few days after the onset of ritonavir treatment.
AIDS, 11 (1997), pp. 388-389
[104.]
J.T. Wilde, C.A. Lee, P. Collins, P.L. Giangrande, M. Winter, C.R. Shiach.
Increased bleeding associated with protease inhibitor therapy in HIV-positive patients with bleeding disorders.
Br J Haematol, 107 (1999), pp. 556-559
[105.]
D. Calista.
Maculo-papular rash induced by lopinavir/ritonavir.
Eur J Dermatol, 15 (2005), pp. 97-98
[106.]
R.S. Cvetkovic, K.L. Goa.
Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Drugs, 63 (2003), pp. 769-802
[107.]
J. Ghosn, C. Duvivier, R. Tubiana, C. Katlama, E. Caumes.
Acute generalized exanthematous pustulosis induced by HIV postexposure prophylaxis with lopinavir-ritonavir.
Clin Infect Dis, 41 (2005), pp. 1360-1361
[108.]
C. Fortuny, M.A. Vicente, M.M. Medina, A. González-Ensenat.
Rash as side-effect of nelfinavir in children.
AIDS, 14 (2000), pp. 335-336
[109.]
D.P. Figgitt, G.L. Plosker.
Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.
Drugs, 60 (2000), pp. 481-516
[110.]
K.J. Smith, J. Yeager, H. Skelton.
Fixed drug eruptions to human immunodeficiency virus-1 protease inhibitor.
Cutis, 66 (2000), pp. 29-32
[111.]
B. Donovan, N.J. Bodsworth, B.P. Mulhall, D. Allen.
Gynaecomastia associated with saquinavir therapy.
Int J STD AIDS, 10 (1999), pp. 49-50
[112.]
A.J. Busti, R.G. Hall, D.M. Margolis.
Atazanavir for the treatment of human immunodeficiency virus infection.
Pharmacotherapy, 24 (2004), pp. 1732-1747
[113.]
Z. Ouagari, R. Tubiana, H.A. Mohand, S. Domínguez, C. Duvivier, F. Bricaire, et al.
Skin rash associated with atazanavir: report of three cases.
AIDS, 20 (2006), pp. 1207-1208
[114.]
A. Kohli-Pamnani, P. Huynh, F. Lobo.
Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virus.
Ann Allergy Asthma Immunol, 96 (2006), pp. 620-623
[115.]
T.M. Chapman, G.L. Plosker, C.M. Perry.
Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection.
Drugs, 64 (2004), pp. 2101-2124
[116.]
H.A. Ward, G.G. Russo, J. Shrum.
Cutaneous manifestations of antiretroviral therapy.
J Am Acad Dermatol, 46 (2002), pp. 284-293
[117.]
Y. Bourezane, D. Salard, B. Hoen, S. Vandel, C. Drobacheff, R. Laurent.
DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy.
Clin Infect Dis, 27 (1998), pp. 1321-1322
[118.]
L.J. Scott, C.M. Perry.
Delavirdine: a review of its use in HIV infection.
Drugs, 60 (2000), pp. 1411-1444
[119.]
E.J. Phillips, B. Kuriakose, S.R. Knowles.
Efavirenz-induced skin eruption and successful desensitization.
Ann Pharmacother, 36 (2002), pp. 430-432
[120.]
H. Yazaki, Y. Kikuchi, S. Oka.
Skin eruption 8 days after a single dose of efavirenz-containing combination therapy.
Jpn J Infect Dis, 54 (2001), pp. 246-247
[121.]
P. Domingo, M. Barcelo.
Efavirenz-induced leukocytoclastic vasculitis.
Arch Intern Med, 162 (2002), pp. 355-356
[122.]
A. Ángel-Moreno-Maroto, L. Suárez-Castellano, M. Hernández-Cabrera, J.L. Pérez-Arellano.
Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.
J Infect, 52 (2006), pp. 39-40
Copyright © 2009. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
